| Interim analysis from the multicenter ROSE study: Radiation during osimertinib treatment safety and efficacy cohort. |
|
|
| Ann Oncol 35 (Supplement 2, 1266P): 810-1 |
|
2024 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1016/j.annonc.2024.08.1323 |
|
|
| Patient-reported outcomes in advanced NSCLC before and during the COVID-19 pandemic: Real-world data from the German prospective CRISP Registry (AIO-TRK-0315) |
|
|
| Int J Cancer 154 (11): 1967-78 |
|
2024 |
|
Thorakale Onkologie
|
|
|
| doi.org/10.1002/ijC.34868 |
|
|
| Anemia Diagnosis and Therapy in Malignant Diseases, Implementation of Guidelines, A Representative Study. |
|
|
| Support Care Cancer 32:113 |
|
2024 |
|
Supportive Therapie
|
|
|
| doi.org/10.1007/s00520-023-08267-4 |
|
|
| Exploratory biomarker analysis of the NEONAX trial for response prediction to perioperative (PO) and adjuvant (A) Gem-nabPac chemotherapy (CTX) in resectable PDAC patients (rPDAC Pts). |
|
|
| Ann Oncol 35 (Supplement 2, 1505P): 922-3 |
|
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1016/j.annonc.2024.08.1568 |
|
|
| Exploration of circulating free bacterial DNA as a biomarker for therapy response in metastatic and locally advanced pancreatic cancer patients treated with systemic chemotherapy. |
|
|
| Ann Oncol 35 (Supplement 2, 1510P): 924 |
|
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1016/j.annonc.2024.08.1573 |
|
|
| Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma |
|
|
| J Clin Oncol 42 (suppl 16) |
|
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1200/JCO.2024.42.16_suppl.TPS4203 |
|
|
| Sequential therapy of refractory metastatic pancreatic cancer with 5‑FU/LV/irinotecan (FOLFIRI) vs. 5‑FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116) |
|
|
| J Cancer Res Clin Oncol 150(7): 332 |
|
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1007/s00432-024-05827-x |
|
|
| Perioperative or adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer: Quality of life results of the randomized phase II AIO-NEONAX trial. |
|
|
| Oncol Res Treat 47 (suppl 1): 77-8 |
|
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1159/000535363 |
|
|
| Alternating application of gemcitabine/nab-paclitaxel (Gem/nab-Pac) and Gem monotherapy or continuous application of Gem/nab-Pac after induction treatment for first-line treatment of metastatic pancreatic cancer (mPC): first results from the randomized phase 2 ALPACA Study from the German AIO study group (AIO-PAK-0114). |
|
|
| J Clin Oncol 42 (suppl 3) |
|
2024 |
|
Pankreaskarzinom
|
|
|
| doi.org/10.1200/JCO.2024.42.3_suppl.605 |
|
|
| Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114) |
|
|
| Oncol Res Treat 47(6): 251-61 |
|
2024 |
|
Ösophagus-/Magenkarzinome
|
|
|
| doi.org/10.1159/000538143 |
|
|
